When: Decisive close above $270 on volume >5M shares with sustained Skyrizi/Rinvoq growth above 25% YoY and raised guidance

Then: Add final 25% of position

When: Close below $248 on volume (below Aug 8 swing low of $243.80 and Sep 8 swing low of $248.78)

Then: Exit position; thesis invalidated

HOLD - Do not add at 265, hold existing position, trim 25-30% on push above 267, add 50% incremental on pullback to 256, add 25% tranche on confirmed breakout above 269.21 with 5M+ volume

• Three failed tests of the 266-269 resistance zone over six weeks is a pattern, not noise - resistance formed by actual selling at those levels
• Today's volume at 3.4 million shares vs 4-7 million typical range means institutions were not committed enough to clear the level
• 10-year Treasury at 4% creates a 139 basis point yield shortfall versus ABBV's 2.61% dividend, pressuring the dividend rotation thesis
• Polymarket pricing 97% probability of no rate cuts represents a structural headwind for dividend-focused investors through year-end
• Single Q2 2026 data point (10.2% revenue growth) does not establish a multi-quarter track record for the growth thesis
• TTM GAAP net income of $6.27 billion on $64 billion revenue while operating income is roughly double indicates Allergan amortization distortion that affects how quant models price the stock
• Rinvoq's 11th EU indication is maintenance news for the franchise, not a growth catalyst - the market priced the first few indications, not the eleventh
• Iambic AI partnership is 'table stakes' - every major pharma is doing AI deals with no premium attached
• ABBV has rallied 39% from April lows of 190 to current 265 - now testing resistance that has rejected the stock three times
• Beta of 0.28 protects against broad market moves but not sector-specific shocks or company-specific events which can drive 10-15% single-session declines
• Structural stop at 248 (just below recent swing low of 248.78) is more durable than ATR-based stop at 256.85 which would cause whipsaw
• Pullback entry at 256 with stop at 248 offers approximately 1:1.6 reward-to-risk vs chase entry at 265 with 248 stop offering approximately 1:0.6 reward-to-risk
• Aggressive analyst's thesis requires three simultaneous successes: clean 269 breakout, Q3 earnings validation, and continued institutional accumulation
• Conservative plan only requires one of those to materialize to add while protecting capital if none do

→ vs aggressive: The '269 is a launchpad' thesis assumes sellers who defended the zone three times will suddenly capitulate with no new catalyst - the coiled spring analogy ignores that resistance resolves in both directions

→ vs aggressive: Volume dismissal is intellectually dishonest - today's session WAS the breakout test, and 3.4M shares below the 4-7M typical range shows institutions weren't committed to clearing 269

→ vs aggressive: Macro rotation thesis is a half-truth - with Treasuries yielding 4%, a 2.61% dividend creates a 139bp yield shortfall that undermines the defensive rotation argument that worked in 2022 near zero rates

→ vs aggressive: PEG argument assumes the consensus growth rate is correct despite only one quarter of data (Q2 2026 at 10.2%) - Q3 earnings in late October will either confirm or expose post-Humira bounce as fading

→ vs aggressive: Catalyst optimism overstated - Rinvoq 11th indication is maintenance, Iambic AI is table stakes, Vraylar data incremental - none are binary catalysts; Q3 earnings has two-sided risk with 8-12% downside on miss

→ vs aggressive: Waiting for 256 is not anchoring to yesterday's price - it's buying pullback support with better risk-adjusted entry (1:1.6 vs 1:0.6 reward-to-risk)

→ vs aggressive: ATR-based stop at 256.85 is too tight and generates whipsaw - structural stop at 248 respects actual support levels

→ vs aggressive: Trimming into resistance is disciplined position management, not underperformance - after a 39% rally into resistance, locking in gains creates dry powder and asymmetric optionality

→ vs aggressive: Beta 0.28 is a measure of historical market sensitivity, not absolute downside protection - in a sector-specific or company-specific event, ABBV can fall 10-15% regardless of beta

Hold existing position with tiered adds on weakness, hedge into catalyst, maintain stop at 248, do not overcommit in either direction

• HOLD decision is correct at the high level
• Would NOT add at 265 - no volume confirmation at resistance, 3.4M share volume shows institutions not committed
• Would NOT trim at 267 - trimming at early stages of confirmed uptrend (39% rally from April lows) locks in opportunity cost
• Maintain existing position with stop at 248 (structural meaning below recent swing low)
• Tiered add approach: Pullback to 260-262 zone with constructive price action (higher low, holding 10 EMA, steady/declining volume on pullback) = add 25% of incremental size
• Tiered add approach: Pullback to 256-258 zone with same constructive price action = add another 25%
• Tiered add approach: Decisive close above 270 on volume above 5 million shares = add final 25% tranche toward 275 target
• Q3 earnings hedge: protective puts at 250 strike for October expiry, costing approximately 1-2% of position value
• ABBV should not exceed standard single-holding position size
• 97% probability of no Fed cuts priced - yield-driven headwind for dividend payers is base case for rest of year
• Aggressive analyst's R/R math was inverted: from 265 to 275 is 10 dollars upside vs 17 dollars downside to 248 stop = 0.59 to 1 R/R, not 1 to 1.5
• Conservative analyst's 256 entry point ignores execution risk - pullbacks in low beta names with momentum are often shallow and brief; next pullback may only reach 260-262, not 50 SMA at 256
• The 256 to 262 zone is more realistic than a single price for adding
• ABBV is a hybrid position (defensive, dividend-paying, low beta with growth optionality from Skyrizi/Rinvoq) that shouldn't be overconcentrated in any single allocation

→ vs aggressive: The coiled spring argument is operationally flawed - momentum alone doesn't break supply zones, requires either fundamental re-rating event or volume surge; 3.4 million share volume on resistance tag shows institutions not committed enough to push through

→ vs aggressive: R/R math was inverted - 10 dollars upside vs 17 dollars downside = 0.59 to 1 R/R, not 1 to 1.5 as claimed; this is actually a worse risk-adjusted setup than conservative trade at 256 with same stop

→ vs aggressive: Macro rotation thesis is less justified than 2022 - with 10-year yielding 4%, ABBV's 2.61% dividend creates 139 basis point yield shortfall vs Treasuries; beta of 0.28 protects against market storms but not yield-driven underperformance

→ vs aggressive: Catalyst pipeline is overstated - Rinvoq 11th EU indication is maintenance news, pJIA is defensive moat not growth catalyst, Iambic AI partnership is table stakes; actual binary event is Q3 earnings where miss causes 8-12% downside vs needing perfection for upside

→ vs conservative: Beta dismissal is practically misleading - beta of 0.28 means in 10% market drawdown ABBV falls approximately 2.8%; base rate protection over full cycle is real and should not be casually dismissed

→ vs conservative: Trimming into 267 is wrong application of logic - trimming should happen when technical structure deteriorates, not when it confirms strength; selling with positive MACD expansion, RSI at 60, price above all three major moving averages is selling the strongest part of the trend

→ vs conservative: Using market's reluctance to re-rate as evidence market is right is circular reasoning - markets can be slow to recognize structural shifts; Q2 2026 showed 10% revenue growth as single data point; if Q3 confirms, market will reprice

→ vs conservative: 256 entry ignores execution risk - pullbacks in low beta names with strong momentum are shallow and brief; September 8 low at 248.78 tagged lower Bollinger and bounced aggressively; next pullback may only reach 260 or 262, not 50 SMA at 256; waiting for 256 risks missing the move entirely